TY - JOUR T1 - The Expression of NRIP1 and LCOR in Endometrioid Endometrial Cancer JF - In Vivo JO - In Vivo SP - 2631 LP - 2640 DO - 10.21873/invivo.12545 VL - 35 IS - 5 AU - STEFANOS FLINDRIS AU - NIKOLAOS KATSOULAS AU - ANNA GOUSSIA AU - ANDREAS CHRISTOS LAZARIS AU - IORDANIS NAVROZOGLOU AU - MINAS PASCHOPOULOS AU - IRENE THYMARA Y1 - 2021/09/01 UR - http://iv.iiarjournals.org/content/35/5/2631.abstract N2 - Background: The aim of the study was to analyze the expression of nuclear receptor interacting protein 1 (NRIP1) and its partner ligand-dependent nuclear receptor co-repressor (LCOR) in endometrioid endometrial cancer and to investigate their association with estrogen receptor (ER), progesterone receptor (PR), Ki-67, clinicopathological parameters and patient survival. Materials and Methods: Immunohistochemical evaluation was carried out to investigate the subcellular expression of NRIP1 and LCOR in endometrioid endometrial cancer samples. Statistical analysis was used to identify the correlations of NRIP1 and LCOR expression with clinicopathological variables and to estimate the survival rates. Results: Endometrial cancer tissues exhibited higher expression of NRIP1 and LCOR in comparison with the normal tissues. Cytoplasmic LCOR expression was positively associated with ER and PR expression, while cytoplasmic NRIP1 expression was positively associated with ER expression. Moreover, cytoplasmic expression of NRIP1 was positively associated with Ki-67. Conclusion: Our study demonstrated that high cytoplasmic expression of LCOR may predict a longer overall survival of patients with endometrioid endometrial cancer. Patients with tumors expressing low levels of LCOR showed a worse survival compared to those expressing high levels. ER -